Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05646875 |
| Other study ID # |
HOT-RESUS 1 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
February 1, 2023 |
| Est. completion date |
December 31, 2023 |
Study information
| Verified date |
May 2023 |
| Source |
University Hospital, Antwerp |
| Contact |
Sebastian Schnaubelt, PD, MD, PhD |
| Phone |
+32 3 821 46 07 |
| Email |
sebastian.schnaubelt[@]muv.ac.at |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
In this prospective pilot study, the effects of hyperbaric oxygen therapy (HBOT) in
post-cardiac arrest syndrome will be evaluated. However, the primary outcome of this pilot
study will be the feasibility of this approach. If feasibility is determined, a larger study
with adequate powering is to follow.
Description:
Cardiac arrest (CA) necessitating cardiopulmonary resuscitation (CPR) currently results in a
survival rate of around 8% in Europe. The much lower percentage of patients being discharged
from hospital with a favourable neurological outcome or with a satisfactory degree of quality
of daily life still shows room for improvement in post CA care. The so- called post-CA
syndrome after return of spontaneous circulation (ROSC) requires a multidisciplinary
management in a coordinated fashion. Despite steady advances in this very specific field of
intensive care medicine, both neurologic and psychologic disability after CA still remain
dismal with hypoxic brain injury as the main determinant (primary cause of death in 68 % of
in-hospital CA and 23 % of out-of-hospital CA [OHCA]), and the optimal treatment approach
might still be missing additional beneficial therapeutic options. The neuropathology of
anoxic brain injury includes neural toxicity, intracellular calcium accumulation, oxygen free
radicals, excitatory amino acid release, reperfusion injury and endothelial dysfunction, with
a clinical presentation through impairment of visual, perceptive, expressive, cognitive, and
motor functions, or psychological distress. As voiced by former patients and relatives, those
functional outcomes are of utmost importance. Therefore, the Core Outcome Set for Cardiac
Arrest (COSCA) was developed.
Hyperoxia vs. hyperbaric oxygenation therapy: It seems intuitive that a hypoxic or anoxic
state such as CA necessitates a hyperoxic environment for convalescence. However, hyperoxia
has been proven to be harmful, mostly through systemically accumulating reactive oxygen
species (ROS), inducing oxidative stress in cellular structures, contributing to deleterious
cell dysfunction and apoptosis induction, and finally leading to unfavourable neurological
outcomes. Hyperoxia is advised against in current guidelines, but not defined or described in
detail, leaving clinicians without a clear recommendation. In parallel, hyperbaric oxygen
therapy (HBOT) was in its beginnings thought to facilitate similar effects. However, HBOT was
then slowly researched in more detail, leading to a paradoxon: On the one side, the described
harmful effects of hyperoxia are known, on the other side HBOT was shown to provide
antioxidant effects, balancing out the negative features. HBOT has thus been described as
safe due to its balance between oxidation and antioxidation. Key molecular changes following
HBOT include a preservation of mitochondrial properties (e.g., through upregulation of ATP
production), a reduction of neuroinflammatory processes (e.g., through reduced cytokine
secretion), an upregulation of angiogenesis (e.g., through an upregulation of cerebral blood
flow and vascular endothelial growth factor [VEGF], or downregulation of metalloproteinases),
suppression of neutrophil-endothelial adhesion, and the mentioned upregulation of both ROS
and antioxidants. HBOT has been shown to restore and increase perfusion and oxygenation of
at-risk tissue, to enhance cerebral microcirculation and stabilize the blood-brain barrier
through metalloprotease regulation, and to decrease intracranial pressure and cerebral edema.
Moreover, it has been linked to several pathways leading to a preservation of neural tissue
and a reduction of apoptosis, for instance shown via reduced levels of hypoxia-inducable
factor 1 alpha (HIF1α). HBOT has also been linked to anti-inflammatory effects, for instance
through a decrease in tumor necrosis factor alpha (TNFα) or an inhibition of the accumulation
of leukocytes in ischemic areas. Mentionable other beneficial results of HBOT include
improvement of left ventricular function, or the induction of significant senolytic effects
including increasing telomere length and clearance of senescent cells. HBOT has in the past
been used quite successfully in animal and human ischemic stroke patients for stimulation of
a hyperoxic environment during ischemic and reperfusion periods, for instance leading to a
reduced infarction area and neuronal death reduction. It was even demonstrated that cognitive
function could be improved, and it was hypothesized that it could signal-induce the
(re-)growth of grey and white cerebral matter. Moreover, HBOT might have the potential to
re-gain suppressed psychological properties such as memories through a complex mechanism of
increased cerebral tissue oxygenation, or even to induce an enhanced multitasking performance
in healthy volunteers. A recent review on the impact of HBOT on cognitive functions yielded
controversial results, concluding with a call for more standardized outcome evaluation.
So far, only four studies and one case report assessed HBOT around CA: In 1952, Koch et al.
described a case of CA and cerebral edema being treated with HBOT "successfully". However,
the given information lacks detail and is highly out-dated. In 1982, Kapp et al. subjected
cats to CA and HBOT, observing a beneficial modification of functional impairment and
metabolic derangements. Rosenthal et al. showed in 2003 that HBOT could inhibit neuronal
death and improve neurologic outcomes after CPR in a canine model, concluding that HBOT has
the potential of overcoming postresuscitative delivery-dependent cerebral ischemia. Of utmost
importance, the authors could demonstrate that only one exposure to hyperbaric conditions was
sufficient to show an effect, and they proved that HBOT is also beneficial in a globally
ischemic model as opposed to a vessel-occluded model such as in the majority of studies
covering stroke patients. Van Meter et al. assessed HBOT during CA (and ongoing
cardiopulmonary resuscitation) in a porcine model, and concluded that the rate of sustained
ROSC was higher in a high-dose HBOT regimen than in a low-dose one or in controls. The same
authors even hypothesized HBOT to be potentially feasible for a more widespread use in CA
patients in the future. Hadanny et al. investigated eleven human CA survivors receiving HBOT
in 2015, and found that the treatment significantly improved memory, attention and executive
functions evaluated via NeuroTrax®, a validated psychologic test series. The findings
correlated with increased activities in the respective brain areas in imaging. Further
research was recommended, but never conducted. Apart from these data, cases on HBOT after CA
due to carbon monoxide poisoning exist, but focus on the treatment of this intoxication per
se and not on other effects. Interestingly, HBOT was also shown to be stimulating the
regeneration of peripheral nerval function after brain injury, potentially inhibiting the
development of polyneuropathy and/or improving motor function after CA.
Assessing HBOT effects: In terms of assessing the effects of HBOT, apart from the mentioned
psychological function tests, several ways of measuring the proposed molecular therapeutic
effects come to mind. For instance, several biomarkers have been suggested, such as
metalloproteases, VEGF, HIF1α, laminin-5, or interleukins. Moreover, a general heterogeneity
and differences of regional cerebral oxygenation (rSO2) must be taken into account.
Techniques such as near-infrared spectroscopy (NIRS) have in the past shown the ability to
detect oxygenation responses of the brain during an after CA and CPR. It is not yet known
whether NIRS can depict HBOT effects, but a hypothesis of "selective neuronal vulnerability"
could be assessed through it. Lastly, endothelial dysfunction that has been reported to be
occurring in CA patients, could be assessed via non-invasive function tests and biomarkers of
endothelial function in order to depict the potential ameliorating effect of HBOT.
Knowledge gaps:
Lack of data on HBOT in immediate post ROSC patients: No randomized controlled study in
humans has been carried out. There is an urgent need to determine the value of HBOT in the
burden of CA and post CA pathologies. Insufficient data on HBOT in CA survivors: Preliminary
data on HBOT in CA survivors are scarce, not robust, and highly heterogenic. Need for robust
comparison data from healthy volunteers: Baseline values and potential normal dynamics of the
outcome values must be acquired in individuals not being associated with CA to correctly
interpret gained data from CA patients / survivors.
Experimental design Project aims: This is a pilot study that aims at general project
feasibility. It should serve as a steppingstone for a large randomized controlled trial. Due
to substantial costs and organizational efforts necessary for a larger trial, the pilot study
is needed as a proof of concept beforehand. The goal of the overall project is to determine
the effect of HBOT in a comprehensive approach towards resuscitation medicine, including
comparison data from healthy volunteers. The pilot study should clarify feasibility (=
primary outcome; defined as successfully recruiting the given number of individuals and
successfully conducting the HBOT intervention) and potentially needed adaptations to the main
study protocol in each study arm. The following main study will assess the primary null
hypothesis "HBOT of any sub-kind is not associated with a beneficial dynamic in markers of
inflammation" among assessing several other secondary outcomes (if deemed feasible in this
pilot).
Secondary outcomes include the feasibility of integrating the HBOT study intervention into
the ongoing clinical work, and successfully collecting further outcome values. These include
(always obtained before and after treatment, except for the control groups): Baseline
characteristics (all patients & probands; also including CA details); NIRS (ICU patients post
ROSC, noninvasively) for assessing regional cerebral oxygen saturation and as a
prognosticator after CA; PWV (all patients & probands, noninvasively): for assessing arterial
stiffness at baseline and after a potential impact of the intervention as a marker of vessel
remodeling and due to its link to inflammation and endothelial dysfunction; Laboratory
markers (all patients and probands) for biobanking (35ml) including markers suggested by the
study collaborators and past literature. Survival to hospital discharge and 30 days and 6
months; Neuropsychological testing; Neurological function; Health-related quality of life.
All measured values eligible for follow-up are - in addition to the timepoint before HBOT -
assessed again after HBOT.
Methodology: Randomized controlled pilot trial in a multiphase fashion. The study collective
consists of three study arms: intensive care unit (ICU) patients after ROSC, healthy
volunteers, and survivors of CA. ICU patients: Inclusion criteria: sustained ROSC since a
maximum of 24 hours, hemodynamic and respiratory stable enough for transportation to HBOT.
Exclusion criteria: traumatic CA, age <18 years, pregnancy, (tension-) pneumothorax. Healthy
volunteers: Inclusion criteria: able to come to the study site themselves. Exclusion
criteria: age <18 years, (suspected or desired) pregnancy, known chronic illnesses,
especially known claustrophobia, history of CA, history of pneumothorax, acute or chronic ear
/ nose condition. CA survivors after hospital discharge: Inclusion criteria: history of CA
from hospital discharge up to a maximum of 3 years ago, able to come to the study site
themselves. Exclusion criteria: age <18 years, (suspected or desired) pregnancy, known
claustrophobia, history of pneumothorax, acute or chronic ear / nose condition. Each study
arm consists of three groups (one not receiving the intervention, one receiving HBOT only
once, one receiving HBOT multiple times).
The intervention is defined as HBOT (carried out in the routine way that is well-established
at the research facility). The details of the HBOT sessions with welcoming of the patient
etc. cannot be described in detail in this short study overview.
Risks and Ethics: HBOT was repeatedly shown to provide antioxidant effects, balancing out the
negative features. HBOT has therefore been described as safe due to its balance between
oxidation and antioxidation. A safe practice of transporting the ICU patient to the
hyperbaric chamber and monitoring them continuously during preparations and treatment itself
is given at all times and provided by the ICU staff. Mechanical ventilation and various
potentially necessary treatments of ICU patients have been decided to be feasible and safe in
hyperbaric conditions, also by the European Committee for Hyperbaric Medicine. The desired
pressure (2 ATM), has in the past been shown to be safe with a remarkably low incidence of
side effects. Also, past research efforts have shown that the inclusion of healthy volunteers
is both feasible and safe. A positive vote of the respective Ethics Committee of the research
institution in Antwerp hqs already been obtained.
